Materials Map

Discover the materials research landscape. Find experts, partners, networks.

  • About
  • Privacy Policy
  • Legal Notice
  • Contact

The Materials Map is an open tool for improving networking and interdisciplinary exchange within materials research. It enables cross-database search for cooperation and network partners and discovering of the research landscape.

The dashboard provides detailed information about the selected scientist, e.g. publications. The dashboard can be filtered and shows the relationship to co-authors in different diagrams. In addition, a link is provided to find contact information.

×

Materials Map under construction

The Materials Map is still under development. In its current state, it is only based on one single data source and, thus, incomplete and contains duplicates. We are working on incorporating new open data sources like ORCID to improve the quality and the timeliness of our data. We will update Materials Map as soon as possible and kindly ask for your patience.

To Graph

1.080 Topics available

To Map

977 Locations available

693.932 PEOPLE
693.932 People People

693.932 People

Show results for 693.932 people that are selected by your search filters.

←

Page 1 of 27758

→
←

Page 1 of 0

→
PeopleLocationsStatistics
Naji, M.
  • 2
  • 13
  • 3
  • 2025
Motta, Antonella
  • 8
  • 52
  • 159
  • 2025
Aletan, Dirar
  • 1
  • 1
  • 0
  • 2025
Mohamed, Tarek
  • 1
  • 7
  • 2
  • 2025
Ertürk, Emre
  • 2
  • 3
  • 0
  • 2025
Taccardi, Nicola
  • 9
  • 81
  • 75
  • 2025
Kononenko, Denys
  • 1
  • 8
  • 2
  • 2025
Petrov, R. H.Madrid
  • 46
  • 125
  • 1k
  • 2025
Alshaaer, MazenBrussels
  • 17
  • 31
  • 172
  • 2025
Bih, L.
  • 15
  • 44
  • 145
  • 2025
Casati, R.
  • 31
  • 86
  • 661
  • 2025
Muller, Hermance
  • 1
  • 11
  • 0
  • 2025
Kočí, JanPrague
  • 28
  • 34
  • 209
  • 2025
Šuljagić, Marija
  • 10
  • 33
  • 43
  • 2025
Kalteremidou, Kalliopi-ArtemiBrussels
  • 14
  • 22
  • 158
  • 2025
Azam, Siraj
  • 1
  • 3
  • 2
  • 2025
Ospanova, Alyiya
  • 1
  • 6
  • 0
  • 2025
Blanpain, Bart
  • 568
  • 653
  • 13k
  • 2025
Ali, M. A.
  • 7
  • 75
  • 187
  • 2025
Popa, V.
  • 5
  • 12
  • 45
  • 2025
Rančić, M.
  • 2
  • 13
  • 0
  • 2025
Ollier, Nadège
  • 28
  • 75
  • 239
  • 2025
Azevedo, Nuno Monteiro
  • 4
  • 8
  • 25
  • 2025
Landes, Michael
  • 1
  • 9
  • 2
  • 2025
Rignanese, Gian-Marco
  • 15
  • 98
  • 805
  • 2025

Perera, Rafael

  • Google
  • 3
  • 39
  • 54

in Cooperation with on an Cooperation-Score of 37%

Topics

Publications (3/3 displayed)

  • 2021Rapid community point-of-care testing for COVID-19 (RAPTOR-C19): protocol for a platform diagnostic study.12citations
  • 2020Measuring the complexity of general practice consultations19citations
  • 2017What carcinoembryonic antigen level should trigger further investigation during colorectal cancer follow-up? A systematic review and secondary analysis of a randomised controlled trial23citations

Places of action

Chart of shared publication
Fuller, Alice
1 / 1 shared
Bankhead, Clare R.
1 / 1 shared
Lay-Flurrie, Sarah
1 / 1 shared
Nicholson, Brian D.
1 / 1 shared
Murphy, Mairead
1 / 1 shared
Holt, Tim A.
1 / 1 shared
Ordóñez-Mena, José M.
1 / 1 shared
Salisbury, Chris
1 / 3 shared
Caddick, Barbara
1 / 1 shared
Hobbs, F. D. Richard
1 / 1 shared
Chart of publication period
2021
2020
2017

Co-Authors (by relevance)

  • Fuller, Alice
  • Bankhead, Clare R.
  • Lay-Flurrie, Sarah
  • Nicholson, Brian D.
  • Murphy, Mairead
  • Holt, Tim A.
  • Ordóñez-Mena, José M.
  • Salisbury, Chris
  • Caddick, Barbara
  • Hobbs, F. D. Richard
OrganizationsLocationPeople

article

What carcinoembryonic antigen level should trigger further investigation during colorectal cancer follow-up? A systematic review and secondary analysis of a randomised controlled trial

  • Perera, Rafael
Abstract

<jats:sec id="abs1-1"><jats:title>Background</jats:title><jats:p>Following primary surgical and adjuvant treatment for colorectal cancer, many patients are routinely followed up with blood carcinoembryonic antigen (CEA) testing.</jats:p></jats:sec><jats:sec id="abs1-2"><jats:title>Objective</jats:title><jats:p>To determine how the CEA test result should be interpreted to inform the decision to undertake further investigation to detect treatable recurrences.</jats:p></jats:sec><jats:sec id="abs1-3"><jats:title>Design</jats:title><jats:p>Two studies were conducted: (1) a Cochrane review of existing studies describing the diagnostic accuracy of blood CEA testing for detecting colorectal recurrence; and (2) a secondary analysis of data from the two arms of the FACS (Follow-up After Colorectal Surgery) trial in which CEA testing was carried out.</jats:p></jats:sec><jats:sec id="abs1-4"><jats:title>Setting and participants</jats:title><jats:p>The secondary analysis was based on data from 582 patients recruited into the FACS trial between 2003 and 2009 from 39 NHS hospitals in England with access to high-volume services offering surgical treatment of metastatic recurrence and followed up for 5 years. CEA testing was undertaken in general practice.</jats:p></jats:sec><jats:sec id="abs1-5"><jats:title>Results</jats:title><jats:p>In the systematic review we identified 52 studies for meta-analysis, including in aggregate 9717 participants (median study sample size 139, interquartile range 72–247). Pooled sensitivity at the most commonly recommended threshold in national guidelines of 5 µg/l was 71% [95% confidence interval (CI) 64% to 76%] and specificity was 88% (95% CI 84% to 92%). In the secondary analysis of FACS data, the diagnostic accuracy of a single CEA test was less than was suggested by the review [area under the receiver operating characteristic curve (AUC) 0.74, 95% CI 0.68 to 0.80]. At the commonly recommended threshold of 5 µg/l, sensitivity was estimated as 50.0% (95% CI 40.1% to 59.9%) and lead time as about 3 months. About four in 10 patients without a recurrence will have at least one false alarm and six out of 10 tests will be false alarms (some patients will have multiple false alarms, particularly smokers). Making decisions to further investigate based on the trend in serial CEA measurements is better (AUC for positive trend 0.85, 95% CI 0.78 to 0.91), but to maintain approximately 70% sensitivity with 90% specificity it is necessary to increase the frequency of testing in year 1 and to apply a reducing threshold for investigation as measurements accrue.</jats:p></jats:sec><jats:sec id="abs1-6"><jats:title>Limitations</jats:title><jats:p>The reference standards were imperfect and the main analysis was subject to work-up bias and had limited statistical precision and no external validation.</jats:p></jats:sec><jats:sec id="abs1-7"><jats:title>Conclusions</jats:title><jats:p>The results suggest that (1) CEA testing should not be used alone as a triage test; (2) in year 1, testing frequency should be increased (to monthly for 3 months and then every 2 months); (3) the threshold for investigating a single test result should be raised to 10 µg/l; (4) after the second CEA test, decisions to investigate further should be made on the basis of the trend in CEA levels; (5) the optimal threshold for investigating the CEA trend falls over time; and (6) continuing smokers should not be monitored with CEA testing. Further research is needed to explore the operational feasibility of monitoring the trend in CEA levels and to externally validate the proposed thresholds for further investigation.</jats:p></jats:sec><jats:sec id="abs1-8"><jats:title>Study registration</jats:title><jats:p>This study is registered as PROSPERO CRD42015019327 and Current Controlled Trials ISRCTN93652154.</jats:p></jats:sec><jats:sec id="abs1-9"><jats:title>Funding</jats:title><jats:p>The main FACS trial and this substudy were funded by the National Institute for Health Research Health Technology Assessment programme.</jats:p></jats:sec>

Topics
  • impedance spectroscopy
  • laser emission spectroscopy
  • size-exclusion chromatography
  • chemical ionisation